money moves

Houston-based Chevron Technology Ventures makes investments in carbon capture and spatial artificial intelligence

Chevron has commissioned a carbon capture study on one of its California sites. Photo courtesy of Chevron

Chevron's Houston-based investment and innovation arm has made moves within the carbon capture and spatial artificial intelligence spaces.

Chevron Technology Ventures has commissioned a carbon capture study with Vancouver-based Svante Inc., an at-scale carbon capture technology company. The study will explore the success of a 10,000 tonne-per-year carbon capture unit in a California Chevron facility. This study is expected to be completed in the first half of this year.

"At Chevron, we believe our industry is well-positioned to help commercialize carbon capture, utilization and storage technologies that will be essential for the energy transition," says Barbara Burger, president of CTV, in a news release. "We have leveraged venture capital and trial capabilities, our experience, and our operations to support the development of low carbon solutions."

Chevron first invested in Svante in 2014, and established its Future Energy Fund in 2018 to focus on "technologies that enable the energy transition," the release reads.

"Demonstrating this technology in the field is an important step in advancing a technology towards commercialization and scale," Burger says in the release. "Commissioning this study reflects our commitment to advance breakthrough innovation that will be important in a low carbon economy and help Chevron deliver on our mission to produce and provide affordable, reliable and ever-cleaner energy."

Barbara Burger leads Houston-based Chevron Technology Ventures as president. Courtesy of CTV

Meanwhile, a Dallas startup is emerging from stealth mode and announcing a $10 million series A round with contribution from CTV.

Worlds, a spin-off company from Hypergiant Sensory Sciences, is developing a technology for extended reality in a physical space. The spatial AI platform's round was led by Ohio-based Align Capital with support from Piva and Hypergiant Industries as well.

"We are creating one of the most powerful manifestations of AI yet, an AI-driven automation platform for physical environments," says Dave Copps, CEO of Worlds, in a news release.

The Worlds technology would be the first of its kind and would use deep learning combined with IoT to create a 4D environment, according to the release. The XR market has been estimated to grow to over $209 billion in the next few years, per a recent report, representing an 800 percent increase in market opportunity.

"Our investment in Worlds reflects our belief that digital innovation plays a critical role in accelerating business value at Chevron," says Burger in the release. "CTV evaluates digital technologies that can help Chevron make better and faster decisions to enable us to deliver on our mission to produce reliable, affordable, and ever-cleaner energy."

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News